Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).
Level 5 - mechanism / opinion, no new human data
Narrative review describing preclinical mechanisms, metabolic effects, and doping detection methodologies with no new human trial data.
What was done
This narrative review summarizes research on the cellular and systemic effects of two metabolic modulators and putative exercise mimetics—the PPAR-delta agonist GW501516 and the AMPK activator AICAR—focusing on their influence on exercise metabolism and the analytical methods developed for their detection in sports doping control.
What was found
The abstract reports no quantitative results or empirical trial metrics. It qualitatively notes that both compounds stimulate fatty acid oxidation, promote muscle remodeling, enhance endurance in animal models, and were placed on the World Anti-Doping Agency Prohibited List in 2009 following evidence of potential athletic abuse and illicit distribution.
Why it matters
It consolidates mechanistic and analytical evidence explaining why molecular exercise mimetics developed for metabolic disorders became targets for anti-doping surveillance and detection.
Limits
The abstract provides no original quantitative data, sample sizes, or human clinical trial results. Discussion of physiological efficacy is primarily grounded in animal models and mechanistic hypotheses.
Cited by
- supports Cardarine (GW501516) is on the World Anti-Doping Agency (WADA) prohibited list.